Sangui Biotech International, Inc. Sustainability Profile
Sangui Biotech International, Inc., often referred to as Sangui Biotech, is a pioneering company headquartered in Delaware, USA. Founded in 2001, the firm operates primarily in the biotechnology sector, focusing on innovative solutions for medical and therapeutic applications. With a commitment to advancing healthcare, Sangui Biotech has developed a range of unique products, including cutting-edge blood substitutes and advanced wound care technologies. The company has achieved significant milestones, positioning itself as a leader in the field of biopharmaceuticals. Its core offerings are distinguished by their ability to enhance patient outcomes and improve quality of life. With a strong presence in both domestic and international markets, Sangui Biotech continues to drive innovation and maintain a competitive edge in the rapidly evolving biotechnology landscape.
DitchCarbon Score
How does Sangui Biotech International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sangui Biotech International, Inc.'s score of 20 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sangui Biotech International, Inc.'s reported carbon emissions
Sangui Biotech International, Inc., headquartered in Delaware, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As there are no emissions data or reduction initiatives available, it is unclear how Sangui Biotech International aligns with industry standards for climate action. The absence of emissions reporting may reflect a broader trend within the biotech sector, where companies are increasingly being urged to disclose their environmental impact and set ambitious sustainability goals. In summary, without available emissions data or climate commitments, Sangui Biotech International, Inc. currently lacks transparency regarding its carbon emissions and climate strategy.
How Carbon Intensive is Sangui Biotech International, Inc.'s Industry?
How Carbon Intensive is Sangui Biotech International, Inc.'s Location?
Sangui Biotech International, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sangui Biotech International, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
